International Gastric Cancer Congress | Conference

Sam Klempner, MD, spoke about clinical management and ctDNA for gastrointestinal cancers.

Sam Klempner, MD, spoke about the importance of expanding minimal residual disease platforms for patients with gastrointestinal cancers.

Sam Klempner, MD, spoke about utilizing ctDNA the treat nonmetastatic gastroesophageal cancers at 2022 IGCC.

Yelena Y. Janjigian, MD, spoke about which biomarkers were most predictive for treatment of localized gastric cancer.

Yelena Y. Janjigian, MD, spoke about using immunotherapy across settings to treat localized gastric cancer.

Laparoscopy compared with open gastrectomy was found to produce better overall survival outcomes at the 5-year follow-up analysis for patients with advanced gastric cancer.

An analysis presented at 2022 IGCC showed that the level of CD8 + cells in the outer margin of gastric cancer tumors was significantly associated with survival outcomes and could inform prognosis.

Men with MSI-high gastric cancer may have shorter overall survival than women, regardless of treatment modality.

Kohie Shitara, MD, spoke about the use of immunotherapy in the first-line setting for metastatic gastric cancer.

Post-resection survival could be predicted by FAM46C expression in patients with gastric adenocarcinoma.